Pranshu Bansal, MD
Hematology & Oncology · Mesa, AZNPI 1447548722
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (50.7%), speaking fees and food and beverage — rather than concentrated in one kind of arrangement. It is spread thinly across 60 manufacturers, the largest accounting for just 17.0%. 2025 is the largest year on record at $75,210, 2.4 times the $30,728 reported in 2019. Among hematology & oncology clinicians in AZ with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 910 payments — averaging $208.28 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Regeneron Healthcare Solutions, Inc.$32K
- Jazz Pharmaceuticals Inc.$18K
- Gilead$17K
- AstraZeneca$16K
- Bristol Myers Squibb$12K
- Rigel Pharmaceuticals, Inc.$11K
- plus $83K from 54 others
Across 86 payments — averaging $3617.55 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Radius Health, Inc.$175K
- Pfizer$47K
- AbbVie$44K
- Bayer$22K
- AstraZeneca$18K
- Stemline Therapeutics Inc.$3K
- plus $2K from 1 others
What the payments were for
- Consulting fees$96,18051%
- Speaking & faculty fees$58,48031%
- Travel & lodging$15,7288%
- Food & beverage$18,86210%
- Education$2810%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$189,531 in reported general payments places this provider in the 95th percentile of 261 hematology & oncology providers in Arizona.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| BrukinsaZanubrutinib | 77 | $902,976 |
| JakafiRuxolitinib Phosphate | 36 | $659,214 |
| TagrissoOsimertinib Mesylate | 38 | $651,656 |
| RevlimidLenalidomide | 26 | $429,172 |
| Lenalidomide | 28 | $307,385 |
| VenclextaVenetoclax | 30 | $234,848 |
| CalquenceAcalabrutinib Maleate | 14 | $159,610 |
| EliquisApixaban | 101 | $83,224 |
| XareltoRivaroxaban | 29 | $38,925 |
| Abiraterone Acetate | 27 | $32,875 |
| OrgovyxRelugolix | 12 | $31,982 |
| Imatinib Mesylate | 12 | $6,214 |
| Dexamethasone | 125 | $2,365 |
| Hydroxyurea | 77 | $2,297 |
| Ondansetron OdtOndansetron | 141 | $1,718 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Beigene USA, Inc.Brukinsa | $2,063 | $902,97677 claims |
| AstraZenecaTagrisso, Calquence | $16,212 | $811,26652 claims |
| Incyte CorporationJakafi | $4,224 | $659,21436 claims |
| Bristol Myers SquibbRevlimid | $12,164 | $429,17226 claims |
| AbbVieVenclexta | $2,761 | $234,84830 claims |
| PfizerEliquis | $3,247 | $83,224101 claims |
| Johnson & JohnsonXarelto | $11,232 | $38,92529 claims |
| Sumitomo Pharma America, Inc.Orgovyx | $100 | $31,98212 claims |
| Lilly USA, LLCOlanzapine | $161 | $75156 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 261 hematology & oncology providers in Arizona.
Other hematology & oncology in Mesa
- Neel DhariaMesa$134K
- Chad CheringtonMesa$36K
- Anu BatraMesa$30K
- Sujith KalmadiChandler$1.4M
- Jeffrey SchriberScottsdale$715K
- Javier MunozPhoenix$638K
- Tanios Bekaii-SaabScottsdale$527K
- Rajesh KukunoorScottsdale$499K
- Sumit MadanGilbert$422K
- Christopher ChenTucson$370K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.